89590-22-7

Basic information

• Product Name: BENZOOXAZOL-4-OL
• Synonyms: BENZOOXAZOL-4-OL;1,3-benzoxazol-4-ol(SALTDATA: FREE);1,3-benzoxazol-4-ol;4-Benzoxazolol;1,3-Benzoxazol-4-ol, 4-Hydroxybenzo[d]oxazole;4-Hydroxy-1,3-benzoxazole;benzo[d]oxazol-4-ol
• CAS NO: 89590-22-7
• Molecular Formula: C₇H₅NO₂
• Molecular Weight: 135.12
• Mol File: 89590-22-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 269.951°C at 760 mmHg
• Flash Point: 117.062°C
• Appearance: /
• Density: 1.379g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.664
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: BENZOOXAZOL-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOOXAZOL-4-OL(89590-22-7)
• EPA Substance Registry System: BENZOOXAZOL-4-OL(89590-22-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 89590-22-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H5NO2/c9-5-2-1-3-6-7(5)8-4-10-6/h1-4,9H

Upstream product

• 3163-15-3 2-aminoresorcinol 
• 149-73-5 trimethyl orthoformate 
• 107-31-3 Methyl formate 
• 601-89-8 2-nitroresorcinol 
• 91668-43-8 triethyl chloroformate 
• 634-60-6 2-aminoresorcinol hydrochloride 
• 77287-34-4 formamide 
• 64-18-6 formic acid 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 166329-37-9 2,6-bis(trimethylsiloxy)phenyl isocyanide 
• 94242-03-2 7-benzoxazoyl 4-methoxycarbanilate 
• 1033810-10-4 4-(2-chloro-4-nitrophenoxy)-1,3-benzoxazole 
• 1068144-14-8 C₇H₄ClNO₃S 
• 1620075-80-0 C₂₀H₁₆BrN₃O₄ 
• 192753-32-5 4-Methoxybenzoxazole 

Relevant articles and documents

Nucleoside analogs useful as PRMT5 inhibitors

The invention relates to the technical field of biological medicines, and particularly discloses a nucleoside analogue used as a PRMT5 inhibitor. According to the nucleoside analogue as shown in the formula (I) or the pharmaceutically acceptable salt of the nucleoside analogue, the nucleoside analogue or the pharmaceutically acceptable salt of the nucleoside analogue shows relatively high inhibition on the activity of PRMT5 and can be used for preventing and/or treating PRMT5-mediated diseases, and the PRMT5-mediated diseases comprise cell abnormal proliferative diseases.

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT